NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1107.95 2.80 (0.25%)

New 52W Low in past week

1.3M NSE+BSE Volume

NSE 13 Mar, 2025 3:31 PM (IST)

92,453.5

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Search Inside the pdf :

Dr. Reddy's Laboratories Ltd.

27 Jan 2025

1107.95

0.25%

Pricing pressure weighs on profitability

Hold: Dr. Reddy's Laboratories Ltd.

Target

KRChoksey

• DRRD revenue, EBITDA, and PAT were largely in-line with our estimates.
• We expect the revenue to grow at 10.3% CAGR and PAT to grow at 5.2% CAGR over FY24-FY27E showing our confidence that the company is getting advanced in the biosimilars pipeline, key launches for cancer therapy and chronic constipation in India and launch of abatacept to gain market share.

Dr. Reddy's Laborato.. has an average target of 1347.12 from 11 brokers.

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1107.95

0.25%

Soft g-Revlimid sales, high expenses dent earnings

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

DRRD delivered in-line sales (adj. for NRT acquisition and milestone income) and marginally better operational performance in 3QFy25. Revenue/EBITDA YoY growth was moderate due to lower off-take of g-Revlimid and PSAI business, which was offset to some extent by healthy performance in the Russia market

Dr. Reddy's Laboratories Ltd. is trading below all available SMAs

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1107.95

0.25%

Dr Reddys Labs (HOLD): NRT business to require huge marketing spend

Hold: Dr. Reddy's Laboratories Ltd.

BOB Capital Markets Ltd.

North America sales missed our estimates and reported US$ 395mn in 3QFY25 vs US$ 445mn in 2QFY25 impacted by gRevlimid

Dr. Reddy's Laborato.. has an average target of 1347.12 from 11 brokers.

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1107.95

0.25%

Core US business weakness coming to the fore

Sell: Dr. Reddy's Laboratories Ltd.

Target

Emkay

Adjusted for the milestone payment received from Journey Medical Corp, 3QFY25 EBITDA for Dr Reddy’s was below street/our estimates. The PAT miss was higher on account of lower other income.

Dr. Reddy's Laboratories Ltd. is trading below all available SMAs

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1107.95

0.25%

Result Update:Dr Reddys Labs

Buy: Dr. Reddy's Laboratories Ltd.

Target

Axis Direct

We maintain our BUY recommendation on the stock.

Number of FII/FPI investors decreased from 957 to 927 in Dec 2024 qtr

Dr. Reddy's Laboratories Ltd.

06 Nov 2024

1107.95

0.25%

Decent print; work on growth levers underway

Hold: Dr. Reddy's Laboratories Ltd.

ICICI Securities Limited

Dr. Reddy’s Laboratories’ (DRL) Q2FY25 performance, adjusted for acquisition-related expenses (INR 561mn) and impairment charge of gNuvaring (INR 924mn), was ahead of our expectations

Number of FII/FPI investors decreased from 957 to 927 in Dec 2024 qtr

Dr. Reddy's Laboratories Ltd.

06 Nov 2024

1107.95

0.25%